Article
Oncology
Wei Wang, Jie Xu, Joseph D. Khoury, Naveen Pemmaraju, Hong Fang, Roberto N. Miranda, C. Cameron Yin, Siba El Hussein, Fuli Jia, Zhenya Tang, Shimin Hu, Marina Konopleva, L. Jeffrey Medeiros, Sa A. Wang
Summary: This study investigated the immunophenotypic and molecular profiles of pDC-AML and BPDCN and found that they have different phenotypes and mutation profiles, indicating that they are two distinct entities.
Article
Medical Laboratory Technology
Xiaofang Zhang, Yiping Wu, Chen Li, Keming Shen, Ruimin Li
Summary: The aim of this study was to investigate the clinical characteristics and diagnosis of acute myeloid leukemia with CD56- blastic plasmacytoid dendritic cell neoplasm. Three cases of elderly men with acute myeloid leukemia were analyzed retrospectively, and their bone marrow features suggested the diagnosis of acute myeloid leukemia with blastic plasmacytoid dendritic cell neoplasm. Flow cytometry and second generation sequencing were performed to detect abnormalities in myeloid cells and abnormal plasmacytoid dendritic cells, as well as gene mutations in RUNX1 and DNMT3A.
CLINICAL LABORATORY
(2023)
Review
Oncology
Hongyan Liao, Jiang Yu, Yu Liu, Sha Zhao, Huanling Zhu, Dongsheng Xu, Nenggang Jiang, Qin Zheng
Summary: This case demonstrates for the first time that prominent pDC proliferation can be associated with lymphoid neoplasms and can exhibit blastic morphology and immunophenotype. The underlying mechanism of the coexistence of these two blastic populations remains unknown.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Yasuhiro Nagate, Aya Nakaya, Ren Kamimura, Yumiko Hirose, Satoshi Nojima, Jiro Fujita, Eiji Kiyohara, Hirohiko Shibayama
Summary: An 84-year-old Japanese man with BPDCN was treated with a combination of venetoclax and azacytidine. Despite experiencing adverse events like neutropenia (Grade 4), thrombocytopenia (Grade 2), and stomatitis (Grade 3), significant improvements were observed after six cycles of treatment. Venetoclax combined with azacytidine is suggested as a useful treatment approach in elderly patients, with careful monitoring and potential modifications to minimize adverse events.
Review
Oncology
Xavier Roussel, Francine Garnache Ottou, Florian Renosi
Summary: Plasmacytoid dendritic cells (pDC) are the main type I interferon-producing cells in humans and are capable of regulating innate and adaptive immune responses. Tumor infiltration by pDC is well-documented in various cancers and is associated with unfavorable clinical outcomes. While Blastic Plasmacytoid Dendritic Cells Neoplasm (BPDCN) is a well-described aggressive leukemia derived from pDCs, the understanding of tumor infiltration by mature pDCs in Myeloid Neoplasms (MN) is limited. This review aims to provide a comprehensive overview of pDC biology in MN, emphasizing the need for further research into pDC oncogenesis and immune responses for better therapeutic strategies.
Article
Oncology
C. Camero Yin, Naveen Pemmaraju, M. James You, Shaoying Li, Jie Xu, Wei Wang, Zhenya Tang, Omar Alswailmi, Kapil N. Bhalla, Muzaffar H. Qazilbash, Marina Konopleva, Joseph D. Khoury
Summary: Mutation and protein-level profiling have expanded our understanding of the pathogenesis of blastic plasmacytoid dendritic cell neoplasm (BPDCN), revealing a high prevalence of somatic mutations involving epigenetic regulators and RNA splicing factors, along with frequent mutations in genes such as ETV6 and IKZF1. Older age, multiple mutations, and mutations in the DNA methylation pathway are poor prognostic factors in BPDCN patients.
Article
Oncology
Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil, Hildegard Greinix, Thomas Heinicke, Wolfgang Bethge, Dietrich Beelen, Christoph Schmid, Hans Martin, Luca Castagna, Christof Scheid, Kerstin Schaefer-Eckart, Joerg Bittenbring, Juergen Finke, Henrik Sengeloev, Mael Heiblig, Jan Cornelissen, Patrice Chevallier, Mohamad Mohty, Stephen Robinson, Silvia Montoto, Peter Dreger
Summary: This retrospective study analyzed the outcomes of 162 adult patients with BPDCN who underwent a first HCT. The study found that MAC (especially TBI-based) significantly improved the prognosis of alloHCT recipients, and autoHCT could be considered for patients who are not eligible for MAC.
Review
Medicine, General & Internal
Hyo-jae Lee, Hye Mi Park, So Yeon Ki, Yoo-Duk Choi, Sook Jung Yun, Hyo Soon Lim
Summary: This case describes a rare presentation of BPDCN in the breast parenchyma, with no previous reports on the radiologic features of the disease within breast tissue. The patient was diagnosed using diagnostic breast imaging tools and underwent chemotherapy with peripheral blood stem cell transplantation, achieving complete remission.
Article
Medicine, General & Internal
Diego Molina Castro, Oliver Perilla Suarez, Jorge Cuervo-Sierra, Alexandra Moreno
Summary: Blastic plasmacytoid dendritic cell neoplasm is a rare hematologic neoplasm with cutaneous, hematologic, and central nervous system involvement. Diagnosis is challenging, and the first-line therapy includes acute lymphoid leukemia-type schemes and allogeneic transplant. New therapies targeting CD 123 and Bcl-2 have shown promise in improving patient survival.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Pathology
Luisa Lorenzi, Silvia Lonardi, Donatella Vairo, Andrea Bernardelli, Michela Tomaselli, Mattia Bugatti, Sara Licini, Mariachiara Arisi, Lorenzo Cerroni, Alessandra Tucci, William Vermi, Silvia Clara Giliani, Fabio Facchetti
Summary: This study identifies EC as a novel pDC marker of diagnostic relevance in BPDCN. The results suggest a scenario where malignant pDCs promote the blunting of IFN-I signaling through EC-driven signaling, leading to a poorly immunogenic tumor microenvironment.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Review
Medicine, General & Internal
Nil Albiol, Silvana Novelli, Anna Mozos, Marta Pratcorona, Rodrigo Martino, Jorge Sierra
Summary: This case report describes a patient with blastic plasmacytoid dendritic cell neoplasm involving the central nervous system, treated with venetoclax. Despite initial response, the disease progressed ultimately leading to fatal outcomes. Further investigations into alternative treatments are warranted for patients with CNS involvement.
JOURNAL OF MEDICAL CASE REPORTS
(2021)
Article
Medicine, General & Internal
Li Zhang, Yidong Wang, Mingming Lu, Mengdan Shen, Zhao Duan
Summary: This study presents a case of a 37-year-old pregnant woman with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). It suggests that pregnant women diagnosed with BPDCN in the third trimester should promptly terminate the pregnancy for further treatment.
Article
Hematology
Corinn Small, Soham Mukerjee, Diwash Jangam, Sumanth Gollapudi, Kunwar Singh, David L. Jaye, Phyu P. Aung, Christiane Querfeld, Keluo Yao, Karen M. Chisholm, Sheeja Pullarkat, Sa Wang, Alejandro Gru, Mohammad Hussaini, Tracy I. George, Robert S. Ohgami
Summary: In this study, the exome sequence data of 9 BPDCN cases were analyzed. Results showed significant genetic changes related to tobacco exposure, aging, nucleotide excision repair deficiency, UV exposure, and endogenous deamination. These findings suggest that environmental and endogenous genetic changes may play a central role in the oncogenesis of BPDCN.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Article
Medicine, Research & Experimental
Wei Cheng, Tian-tian Yu, Ai-ping Tang, Ken He Young, Li Yu
Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy derived from plasmacytoid dendritic cells with unclear pathogenesis. Treatment is based on leukemia or lymphoma experience, relapse is quick with drug resistance.
CURRENT MEDICAL SCIENCE
(2021)
Article
Medicine, General & Internal
Amaranto Suarez, Nathalie Soler, Alejandra Calderon, Bibiana Martinez, Martha Pina
Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive malignancy that affects the skin and hematopoietic system. It is difficult to clinically suspect, and managing skin lesions is challenging due to their slow progression before spreading. We present a case of a patient with isolated skin involvement who later developed CD4+/CD56+ and CD123+ acute leukemia.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2023)
Article
Biophysics
Anastasia Papadopoulou, Kiriakos Koukoulias, Maria Alvanou, Anastasios Kouimtzidis, Evangelia Athanasiou, Nikolaos Savvopoulos, Anthi-Marina Markantonatou, Eleni Siotou, Timoleon-Achilleas Vyzantiadis, Achilles Anagnostopoulos, Evangelia Yannaki
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Stavroula Ntoufa, Marina Gerousi, Stamatia Laidou, Fotis Psomopoulos, Georgios Tsiolas, Theodoros Moysiadis, Nikos Papakonstantinou, Larry Mansouri, Achilles Anagnostopoulos, Niki Stavrogianni, Sarka Pospisilova, Karla Plevova, Antonios M. Makris, Richard Rosenquist, Kostas Stamatopoulos
Summary: Recurrent mutations in the RPS15 gene have been found to rewire the translation program of primary CLL cells, reducing their translational efficiency, with effects not observed in cell lines. Specifically, RPS15 mutations alter the translation efficiency of other ribosomal proteins and regulatory elements, impacting key cellular processes and immune signaling.
Article
Biophysics
Eleni Gavriilaki, Panagiota Anyfanti, Ioanna Sakellari, Ioannis Batsis, Panagiotis Dolgyras, Antonios Lazaridis, Barbara Nikolaidou, Nikolaos Koletsos, Maria Gavriilaki, Ippokratis Zarifis, Marianna Masmanidou, Zoi Bousiou, Anna Vardi, Stella Douma, Achilles Anagnostopoulos, Eugenia Gkaliagkousi
Summary: This study found impaired microvascular function in allogeneic hematopoietic cell transplantation (alloHCT) survivors free of graft-versus-host-disease or relapse, independently of cardiovascular risk factors. The study suggests the need for further research on novel markers for cardiovascular risk prediction and the effects of disease type, phase, and pre-transplant treatments.
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Chrysavgi Lalayanni, Eleni Gavriilaki, Anastasia Athanasiadou, Michael Iskas, Maria Papathanasiou, Anastasia Marvaki, Sotiria Mpesikli, Giorgos Papaioannou, Despina Mallouri, Ioannis Batsis, Apostolia Papalexandri, Ioanna Sakellari, Achilles Anagnostopoulos
Summary: Therapy related acute myeloid leukemia (tAML) and secondary AML after an antecedent hematologic disorder (sAML-AHD) are often considered together, although they have some clinical and prognostic differences. Both sAML groups have poor outcomes after uniform and intensive treatment. Allogeneic hematopoietic cell transplantation (alloHCT) was found to be an independent predictor of outcome in both groups, while karyotype only affected sAML-AHD.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Biotechnology & Applied Microbiology
Evangelia Yannaki, Nikoletta Psatha, Anastasia Papadopoulou, Takis Athanasopoulos, Achilleas Gravanis, Maria G. Roubelakis, Panagiotis Tsirigotis, Achilles Anagnostopoulos, Nicholas P. Anagnou, George Vassilopoulos
Summary: Gene therapy, a relatively new field with around four decades of development, has entered the clinical stage with a focus on hemoglobinopathies and hematopoietic stem cells. Research efforts have been made to efficiently implement gene therapy through advancements in HSC biology and gene expression technologies, potentially transforming the therapeutic landscape for genetic diseases in the near future.
HUMAN GENE THERAPY
(2021)
Article
Cell Biology
Panagiotis G. Asteris, Eleni Gavriilaki, Tasoula Touloumenidou, Evaggelia-Evdoxia Koravou, Maria Koutra, Penelope Georgia Papayanni, Alexandros Pouleres, Vassiliki Karali, Minas E. Lemonis, Anna Mamou, Athanasia D. Skentou, Apostolia Papalexandri, Christos Varelas, Fani Chatzopoulou, Maria Chatzidimitriou, Dimitrios Chatzidimitriou, Anastasia Veleni, Evdoxia Rapti, Ioannis Kioumis, Evaggelos Kaimakamis, Milly Bitzani, Dimitrios Boumpas, Argyris Tsantes, Damianos Sotiropoulos, Anastasia Papadopoulou, Ioannis G. Kalantzis, Lydia A. Vallianatou, Danial J. Armaghani, Liborio Cavaleri, Amir H. Gandomi, Mohsen Hajihassani, Mahdi Hasanipanah, Mohammadreza Koopialipoor, Paulo B. Lourenco, Pijush Samui, Jian Zhou, Ioanna Sakellari, Serena Valsami, Marianna Politou, Styliani Kokoris, Achilles Anagnostopoulos
Summary: This study aimed to develop a predictive model for ICU hospitalization and death in COVID-19 patients and validate the association between complement-related genetic variants and impaired complement phenotype. We identified critical variants associated with severe COVID-19 and developed an artificial neural network (ANN) predicting morbidity and mortality with high accuracy.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Article
Hematology
Fredrik H. Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Ludek Pour, Ivan Spicka, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gabor Mikala, Laura Rosinol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A. Bakker, Roman Hajek, Maria-Victoria Mateos, Paul G. Richardson, Pieter Sonneveld
Summary: In patients with relapsed or refractory multiple myeloma, melphalan flufenamide plus dexamethasone demonstrated superior progression-free survival compared to pomalidomide plus dexamethasone.
LANCET HAEMATOLOGY
(2022)
Article
Medicine, General & Internal
Christos Varelas, Eleni Gavriilaki, Ioanna Sakellari, Philippos Klonizakis, Evaggelia-Evdoxia Koravou, Ioanna Christodoulou, Ioulia Mavrikou, Andreas Kourelis, Fani Chatzopoulou, Dimitrios Chatzidimitriou, Tasoula Touloumenidou, Apostolia Papalexandri, Achilles Anagnostopoulos, Efthimia Vlachaki
Summary: Most SCD patients demonstrated adequate levels of neutralizing antibodies against SARS-CoV-2 after the second dose of mRNA vaccines, with a certain association with complement activation. Further studies are critical to determine the durability of this immune response and the potential benefit of a third dose.
JOURNAL OF CLINICAL MEDICINE
(2022)
Letter
Biophysics
Eleni Gavriilaki, Anastasia Papadopoulou, Tasoula Touloumenidou, Fani Stavridou, Evaggelia-Evdoxia Koravou, Maria Giannaki, Apostolia Papalexandri, Georgios Karavalakis, Ioannis Batsis, Andreas Kourelis, Fani Chatzopoulou, Dimitrios Chatzidimitriou, Damianos Sotiropoulos, Evangelia Yannaki, Ioanna Sakellari, Achilles Anagnostopoulos
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Stamatia Laidou, Dionysios Grigoriadis, Sofia Papanikolaou, Spyros Foutadakis, Stavroula Ntoufa, Maria Tsagiopoulou, Giannis Vatsellas, Achilles Anagnostopoulos, Anastasia Kouvatsi, Niki Stavroyianni, Fotis Psomopoulos, Antonios M. Makris, Marios Agelopoulos, Dimitris Thanos, Anastasia Chatzidimitriou, Nikos Papakonstantinou, Kostas Stamatopoulos
Summary: The high expression of TAp63 in CLL is associated with adverse clinical outcomes and contributes to the antiapoptotic phenotype by modulating BCL2 expression.
Article
Medicine, General & Internal
Anna Waszczuk-Gajda, Olaf Penack, Giulia Sbianchi, Linda Koster, Didier Blaise, Peter Remenyi, Nigel Russell, Per Ljungman, Marek Trneny, Jiri Mayer, Simona Iacobelli, Guido Kobbe, Christof Scheid, Jane Apperley, Cyrille Touzeau, Stig Lenhoff, Esa Jantunen, Achilles Anagnostopoulos, Laura Paris, Paul Browne, Catherine Thieblemont, Nicolaas Schaap, Jorge Sierra, Ibrahim Yakoub-Agha, Laurent Garderet, Jan Styczynski, Helene Schoemans, Ivan Moiseev, Rafael F. Duarte, Zinaida Peric, Silvia Montoto, Anja van Biezen, Malgorzata Mikulska, Mahmoud Aljurf, Tapani Ruutu, Nicolaus Kroeger, Curly Morris, Christian Koenecke, Stefan Schoenland, Grzegorz W. Basak
Summary: This post hoc analysis evaluated the rate of infectious and non-infectious complications after ASCT in multiple myeloma patients. The analysis included 3552 patients and found that complication rates decreased over time. Bacterial infections and gastrointestinal complications were the most common early events. The occurrence of complications was not associated with overall survival.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Anastasia Papadopoulou, Fani Stavridou, Maria Giannaki, Kiriaki Paschoudi, Fani Chatzopoulou, Eleni Gavriilaki, Grigorios Georgolopoulos, Achilles Anagnostopoulos, Evangelia Yannaki
Summary: This study found that despite the decrease in neutralizing antibodies and specific T-cell abundance over time after vaccination, individuals still maintain a strong cellular immune response when exposed to the SARS-CoV-2 virus.
Article
Hematology
Nikolaos J. Tsagarakis, Georgios Androutsos, Ioulia Chaliori, Sofia Chaniotaki, Georgios Paterakis, Elpiniki Kritikou-Griva
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2022)
Letter
Biophysics
Raffaella Greco, Jorinde D. Hoogenboom, Edouard F. Bonneville, Achilles Anagnostopoulos, Angela Cuoghi, Jean-Hugues Dalle, Eva M. Weissinger, Peter Lang, Federica Galaverna, Massimo Martino, Alexei Maschan, Christine Mauz-Korholz, Maddalena Noviello, Jakob Passweg, Jacopo Peccatori, Montserrat Rovira, Carlos Solano, Hendrik Veelken, Andrea Velardi, Eva Maria Wagner-Drouet, Xi Zhang, Fabio Ciceri, Chiara Bonini, Luca Vago, Annalisa Ruggeri, Christian Chabannon
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Eleni Gavriilaki, Panagiotis Dolgyras, Sotiria Dimou-Mpesikli, Aikaterini Poulopoulou, Paschalis Evangelidis, Nikolaos Evangelidis, Christos Demosthenous, Evangelia Zachrou, Panagiotis Siasios, Despina Mallouri, Anna Vardi, Zoi Bousiou, Alkistis Panteliadou, Ioannis Batsis, Marianna Masmanidou, Chrysavgi Lalayanni, Evangelia Yannaki, Damianos Sotiropoulos, Achilles Anagnostopoulos, Timoleon-Achilleas Vyzantiadis, Ioanna Sakellari
Summary: This retrospective study investigated the prevalence and outcome of invasive fungal infections (IFD) in patients who received cellular therapies. It was found that CAR T cell and gene therapy recipients did not develop IFD, while autologous HCT recipients with primary refractory/relapsed lymphomas had probable IFD. Among allogeneic HCT recipients, 11 experienced probable IFD, 31 had possible IFD, and 10 had proven IFD. These findings suggest that IFD is associated with poor outcomes in allogeneic HCT recipients.